Juformin

Metformin Hydrochloride, the active ingredient in Juformin, is a biguanide presented as a tablet for oral use. It improves blood‑glucose control in adults with type 2 diabetes mellitus by decreasing hepatic glucose production and increasing peripheral insulin sensitivity.

GNH USA supplies Juformin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juformin belongs to the biguanide class and is used to manage disorders of glucose metabolism.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Prediabetes: helps delay progression to overt diabetes. Polycystic ovary syndrome (off‑label): improves insulin resistance and may restore ovulatory cycles.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption. - Acute pancreatitis: very uncommon inflammatory pancreas condition.

Metformin requires careful monitoring and patient education before and during therapy. - Renal function assessment: ensure eGFR is adequate before initiation and periodically thereafter. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Blood glucose monitoring: adjust dose based on glycaemic response. - Contraindication in severe heart failure: risk of lactic acidosis is heightened. - Use with caution in elderly patients: increased susceptibility to gastrointestinal upset and renal decline. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast media: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates the risk of lactic acidosis. - Rifampicin: reduces metformin exposure, potentially diminishing glucose control.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can increase blood glucose levels. - ACE inhibitors/ARBs: monitor renal function and potassium. - Sulfonylureas: heightened risk of hypoglycaemia when combined. - Digoxin: monitor for altered serum levels.